Characterization of anti-CD19 chimeric antigen receptor (CAR) T cell-mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA-1) with axicabtagene ciloleucel (axi-cel, KTE-C19).
Year: 2017
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Jerome Galon, John Rossi, Sarah Turcan, Corinne Danan, Frederick Lundry Locke, Sattva Swarup Neelapu, David Bernard Miklos, Nancy L. Bartlett, Caron Alyce Jacobson, Ira Braunschweig, Olalekan O. Oluwole, Tanya Siddiqi, Yi Lin, John Timmerman, Patrick Michael Reagan, Lazaros J. Lekakis, Sherryonne Unabia, William Y. Go, Jeffrey S. Wiezorek, Adrian Bot
Institutions: Inserm, Laboratoire d’immunologie intégrative du cancer, Kite Pharma (United States), Moffitt Cancer Center, The University of Texas MD Anderson Cancer Center, Stanford Medicine, Washington University in St. Louis, Dana-Farber Cancer Institute, Albert Einstein College of Medicine, Montefiore Medical Center, Vanderbilt University Medical Center, City Of Hope National Medical Center, Mayo Clinic, University of California, Los Angeles, University of Rochester Medicine, University of Miami
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2890039919